NASDAQ:ARTV Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis $7.63 -0.04 (-0.52%) Closing price 04:00 PM EasternExtended Trading$7.80 +0.17 (+2.16%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Artiva Biotherapeutics Stock (NASDAQ:ARTV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Artiva Biotherapeutics alerts:Sign Up Key Stats Today's Range$7.46▼$8.0250-Day Range$5.01▼$13.3952-Week Range$1.47▼$14.53Volume308,932 shsAverage Volume314,097 shsMarket Capitalization$188.59 millionP/E RatioN/ADividend YieldN/APrice Target$39.00Consensus RatingModerate Buy Company Overview Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches. Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors. By combining gene-editing technologies with optimized cell expansion processes, the company aims to enhance tumor targeting, persistence and safety profiles. Its platform supports rapid manufacturing and scalable production, potentially enabling broader patient access and faster clinical development timelines. Founded in 2016 and headquartered in Cambridge, Massachusetts, Artiva Biotherapeutics operates in key biopharma hubs across North America and Europe. The company’s management team brings collective expertise in immuno-oncology, cell therapy manufacturing and clinical development, positioning Artiva to advance its candidate programs through pivotal trials and, ultimately, regulatory approval.AI Generated. May Contain Errors. Read More Artiva Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreARTV MarketRank™: Artiva Biotherapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 154th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingArtiva Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialArtiva Biotherapeutics has a consensus price target of $39.00, representing about 411.1% upside from its current price of $7.63.Amount of Analyst CoverageArtiva Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Artiva Biotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Artiva Biotherapeutics are expected to decrease in the coming year, from ($2.45) to ($2.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artiva Biotherapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artiva Biotherapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtiva Biotherapeutics has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Artiva Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.18% of the float of Artiva Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArtiva Biotherapeutics has a short interest ratio ("days to cover") of 0.53, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artiva Biotherapeutics has recently increased by 54.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtiva Biotherapeutics does not currently pay a dividend.Dividend GrowthArtiva Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.56 News SentimentArtiva Biotherapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Artiva Biotherapeutics this week, compared to 4 articles on an average week.Search Interest17 people have searched for ARTV on MarketBeat in the last 30 days. This is an increase of 467% compared to the previous 30 days.MarketBeat Follows3 people have added Artiva Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $74,522,102.00 in company stock, which represents 39.5153% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Artiva Biotherapeutics insiders have bought 15,593.99% more of their company's stock than they have sold. Specifically, they have bought $74,999,992.00 in company stock and sold $477,890.00 in company stock.Percentage Held by Insiders21.40% of the stock of Artiva Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsArtiva Biotherapeutics has minimal institutional ownership at this time.Read more about Artiva Biotherapeutics' insider trading history. Receive ARTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTV Stock News HeadlinesArtiva Biotherapeutics (NASDAQ:ARTV) SVP Sells $27,885.95 in StockMay 21, 2026 | insidertrades.comArtiva Biotherapeutics Announces $300 Million Equity OfferingMay 21, 2026 | theglobeandmail.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 27 at 1:00 AM | Weiss Ratings (Ad)Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $39.00 Average Target Price from BrokeragesMay 21, 2026 | americanbankingnews.comArtiva Biotherapeutics (NASDAQ:ARTV) Insider Christopher Horan Sells 7,002 SharesMay 20, 2026 | insidertrades.comArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy ...May 19, 2026 | finance.yahoo.comArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic DiseasesMay 19, 2026 | globenewswire.comArtiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $74,999,992.32 in StockMay 14, 2026 | insidertrades.comSee More Headlines ARTV Stock Analysis - Frequently Asked Questions How have ARTV shares performed this year? Artiva Biotherapeutics' stock was trading at $4.29 on January 1st, 2026. Since then, ARTV shares have increased by 77.9% and is now trading at $7.63. How were Artiva Biotherapeutics' earnings last quarter? Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) issued its quarterly earnings results on Friday, May, 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by $0.07. When did Artiva Biotherapeutics IPO? Artiva Biotherapeutics (ARTV) raised $209 million in an initial public offering (IPO) on Friday, July 19th 2024. The company issued 13,920,000 shares at $14.00-$16.00 per share. Who are Artiva Biotherapeutics' major shareholders? Top institutional investors of Artiva Biotherapeutics include venBio Partners LLC (2.15%), Renaissance Technologies LLC (0.32%), Simplify Asset Management Inc. (0.09%) and Sanctuary Advisors LLC (0.09%). Insiders that own company stock include Ra Capital Management, LP, Yong-Jun Huh, Global Strategic Fund I Venbio, Fred Aslan, Jennifer Bush, Christopher Horan, Heather Raymon and Subhashis Banerjee. View institutional ownership trends. How do I buy shares of Artiva Biotherapeutics? Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artiva Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI). Company Calendar Last Earnings5/08/2026Today5/27/2026Status update6/08/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ARTV's financial health is in the Green zone, according to TradeSmith. ARTV has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARTV Previous SymbolNASDAQ:ARTV CIK1817241 Webwww.artivabio.com Phone(858) 267-4467FaxN/AEmployees81Year Founded2019Price Target and Rating Average Price Target for Artiva Biotherapeutics$39.00 High Price Target$41.00 Low Price Target$35.00 Potential Upside/Downside+411.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.15% Return on Assets-62.74% Debt Debt-to-Equity RatioN/A Current Ratio8.16 Quick Ratio8.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.55 per share Price / Book2.15Miscellaneous Outstanding Shares24,717,000Free Float19,428,000Market Cap$188.59 million OptionableN/A Beta2.86 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ARTV) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTV Stock Alerts